HGS files Benlysta in US
This article was originally published in Scrip
Executive Summary
Human Genome Sciences has filed a BLA for Benlysta (belimumab) in the US for the treatment of systemic lupus erythematosus (SLE) in patients who are autoantibody-positive. The US filing is good news for the company after it previously admitted that it might not be able to meet its second quarter submission target for the product because of the increased analytical work needed following its failure to meet a key secondary endpoint in the pivotal BLISS-76 study (ie, patient response rate at week 76; scripnews.com, 26 April 2010).
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.